v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net income (loss) $ (1,828) $ 3,010
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 49 61
Amortization of right-of-use asset 57 47
Change in fair value of contingent consideration 188 136
Gain on early lease termination 0 (5,974)
Gain on settlement of accounts payables 0 (191)
Loss on disposal of assets 37 26
Changes in operating assets and liabilities:    
Other receivable (2) 1,339
Prepaid expenses and other current assets 2 59
Accounts payable 755 (427)
Accrued expenses (400) 316
Net cash used in operating activities (1,142) (1,598)
Cash flows from investing activities:    
Acquisition of GPCR Therapeutics USA Inc. 0 (2,090)
Net cash used in investing activities 0 (2,090)
Cash flows from financing activities:    
Proceeds from common stock offering 0 1,600
Net cash provided by provided by financing activities 0 1,600
Net decrease in cash and cash equivalents (1,142) (2,088)
Cash and cash equivalents - beginning of period 3,746 12,508
Cash and cash equivalents - end of period $ 2,604 $ 10,420